Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
49 participants
INTERVENTIONAL
2021-04-12
2022-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of improving the time to resolution of disease.
2. To determine the efficacy of IC14 in reducing the severity of respiratory disease in patients hospitalized with respiratory disease due to SARS-CoV-2.
3. To determine the safety of IC14 in patients hospitalized with respiratory disease due to SARS-CoV-2.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
NCT04385849
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
NCT04847544
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
NCT04501952
Collection of Anti-SARS-CoV-2 Immune Plasma
NCT04344977
Anti-SARS Cov-2 T Cell Infusions for COVID 19
NCT04401410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be randomized to IC14 or matching placebo and followed for 60 days after randomization. The study drug will be administered daily on Days 1-4 by intravenous infusion. All participants will receive standard of care antiviral therapy with remdesivir.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anti-CD14 + SOC
Anti-CD14: Anticipated 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously.
Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness.
anti-CD14
4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
remdesivir
Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Placebo + SOC
Anticipated 150 participants randomized to Placebo diluent on Days 1-4 intravenously.
Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness.
Placebo
Placebo administered intravenously on Days 1-4
remdesivir
Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anti-CD14
4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
Placebo
Placebo administered intravenously on Days 1-4
remdesivir
Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient or legally authorized representative able to provide informed consent
* Presence of SARS-CoV-2 infection documented by positive RT-PCR testing or history of positive RT-PCR test for SARS-CoV-2 within 7 days of screening
* Radiologic findings compatible with diagnosis of SARS-CoV-2 pulmonary infection
* Hypoxemia as defined by any of the following:
* SpO2 ≤94% on room air, or
* Requirement for ≥2L/m O2 per standard nasal cannula to maintain SpO2≥94%, but not requiring high-flow nasal cannula (defined as ≥30 L/m), and
* Negative pregnancy test for women of childbearing potential and, must be willing to use birth control for the duration of the study.
Exclusion Criteria
* Receiving non-invasive positive-pressure ventilation through nasal mask, face mask, or nasal plugs
* Receiving invasive mechanical ventilation
* Patient, surrogate, or physician not committed to full support
--Exception: a participant will not be excluded if he/she would receive all supportive care other than attempts at resuscitation from cardiac arrest)
* Anticipated survival \<48 hours
* Underlying malignancy, or other condition, with estimated life expectancy of less than two months
* Significant pre-existing organ dysfunction prior to randomization
* Lung: Currently receiving home oxygen therapy as documented in medical record
* Heart: Pre-existing congestive heart failure defined as an ejection fraction \<20% as documented in the medical record
* Renal: End-stage renal disease requiring renal replacement therapy or eGFR \<30 mL/min
* Liver: Severe chronic liver disease defined as Child-Pugh Class C or AST or ALT \>5x upper limit of normal
* Hematologic: Baseline platelet count \<50,000/mm\^3
* Presence of co-existing infection, including, but not limited to:
* HIV infection not virally suppressed and with pre-hospitalization CD4 counts ≤ 500 cell/mm\^3
* Active tuberculosis or a history of inadequately treated tuberculosis
* Active hepatitis B or hepatitis C viral infection
* Ongoing immunosuppression
* Solid organ transplant recipient
* High-dose corticosteroids (equivalent to \>20 mg/prednisone/day) within the past 28 days, except for dexamethasone except for dexamethasone or equivalent treatment for COVID-19 illness
* Oncolytic drug therapy within the past 14 days
* Current treatment, or treatment within 30 days or five half-lives (whichever is longer) with etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizumab (Cimzia®), golimumab (Simponi®), anakinra (Kineret®), rilonacept (Arcalyst®), tocilizumab (Actemra®), sarilumab (Kevzara®), siltuximab (Sylvant®), or other potent immunosuppressant or immunomodulatory drugs or treatments
* Current treatment with an anti-viral medication for COVID-19 (e.g. hydroxychloroquine, lopinavir/ritonavir), other than remdesivir
* Current enrollment in an interventional trial for COVID-19
* History of hypersensitivity or idiosyncratic reaction to IC14
* Women who are currently breastfeeding
* Received a live-attenuated vaccine within 30 days prior to enrollment
* Received five or more doses of remdesivir, including the loading dose, outside of the study as treatment for COVID-19, or
* Any condition that in the opinion of the treating physician will increase the risk for the participant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Washington
OTHER
Implicit Bioscience
INDUSTRY
Vanderbilt University Medical Center
OTHER
PPD Development, LP
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark M. Wurfel, MD, PhD
Role: STUDY_CHAIR
University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine
Thomas R. Martin, MD
Role: STUDY_CHAIR
University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarasota Memorial Health Care System
Sarasota, Florida, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Harborview Medical Center
Seattle, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
University of Washington Medical Center-Montlake
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
National Institutes of Health News Release Describing Study
National Institute of Allergy and Infectious Diseases (NIAID)
NIAID Division of Allergy, Immunology, and Transplantation (DAIT)
Centers for Disease Control and Prevention -COVID-19 resources
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIAID CRMS ID#: 38756
Identifier Type: OTHER
Identifier Source: secondary_id
DAIT COVID-19-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.